Clinical outcomes by treatment group during the 3-month main study period
| Study outcome . | Rivaroxaban, N = 40, n (%) . | Standard of care, N = 16, n (%) . | Total, N = 56, n (%) . |
|---|---|---|---|
| Recurrent VTE | 0 (0) | 0 (0) | 0 (0) |
| Major bleeding | 0 (0) | 0 (0) | 0 (0) |
| CRNM bleeding, Mallory-Weiss tear | 1 (2.5) | 0 (0) | 1 (1.8) |
| Mortality | 1 (2.5) | 0 (0) | 1 (1.8) |
| Repeat imaging | n = 37 | n = 15 | n = 52 |
| Normalized | 13 (35.1) | 7 (46.7) | 20 (38.5) |
| Improved | 19 (51.4) | 5 (33.3) | 24 (46.2) |
| Unchanged | 5 (13.5) | 3 (20.0) | 8 (15.4) |
| Deteriorated | 0 (0) | 0 (0) | 0 (0) |
| Study outcome . | Rivaroxaban, N = 40, n (%) . | Standard of care, N = 16, n (%) . | Total, N = 56, n (%) . |
|---|---|---|---|
| Recurrent VTE | 0 (0) | 0 (0) | 0 (0) |
| Major bleeding | 0 (0) | 0 (0) | 0 (0) |
| CRNM bleeding, Mallory-Weiss tear | 1 (2.5) | 0 (0) | 1 (1.8) |
| Mortality | 1 (2.5) | 0 (0) | 1 (1.8) |
| Repeat imaging | n = 37 | n = 15 | n = 52 |
| Normalized | 13 (35.1) | 7 (46.7) | 20 (38.5) |
| Improved | 19 (51.4) | 5 (33.3) | 24 (46.2) |
| Unchanged | 5 (13.5) | 3 (20.0) | 8 (15.4) |
| Deteriorated | 0 (0) | 0 (0) | 0 (0) |